Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Charles Dinarello to Melanoma, Experimental

This is a "connection" page, showing publications Charles Dinarello has written about Melanoma, Experimental.

 
Connection Strength
 
 
 
0.966
 
  1. Carrascal MT, Mendoza L, Valcárcel M, Salado C, Egilegor E, Tellería N, Vidal-Vanaclocha F, Dinarello CA. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res. 2003 Jan 15; 63(2):491-7.
    View in: PubMed
    Score: 0.182
  2. Tengesdal IW, Dinarello A, Powers NE, Burchill MA, Joosten LAB, Marchetti C, Dinarello CA. Tumor NLRP3-Derived IL-1ß Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression. Front Immunol. 2021; 12:661323.
    View in: PubMed
    Score: 0.165
  3. Tengesdal IW, Menon DR, Osborne DG, Neff CP, Powers NE, Gamboni F, Mauro AG, D'Alessandro A, Stefanoni D, Henen MA, Mills TS, De Graaf DM, Azam T, Vogeli B, Palmer BE, Pietras EM, DeGregori J, Tan AC, Joosten LAB, Fujita M, Dinarello CA, Marchetti C. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. Proc Natl Acad Sci U S A. 2021 03 09; 118(10).
    View in: PubMed
    Score: 0.160
  4. Vidal-Vanaclocha F, Alvarez A, Asumendi A, Urcelay B, Tonino P, Dinarello CA. Interleukin 1 (IL-1)-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. J Natl Cancer Inst. 1996 Feb 21; 88(3-4):198-205.
    View in: PubMed
    Score: 0.113
  5. Vidal-Vanaclocha F, Amézaga C, Asumendi A, Kaplanski G, Dinarello CA. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res. 1994 May 15; 54(10):2667-72.
    View in: PubMed
    Score: 0.100
  6. Carmi Y, Dotan S, Rider P, Kaplanov I, White MR, Baron R, Abutbul S, Huszar M, Dinarello CA, Apte RN, Voronov E. The role of IL-1ß in the early tumor cell-induced angiogenic response. J Immunol. 2013 Apr 01; 190(7):3500-9.
    View in: PubMed
    Score: 0.092
  7. Lavi G, Voronov E, Dinarello CA, Apte RN, Cohen S. Sustained delivery of IL-1 Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases. J Control Release. 2007 Nov 06; 123(2):123-30.
    View in: PubMed
    Score: 0.062
  8. Clarke JH, Cha JY, Walsh MD, Gamboni-Robertson F, Banerjee A, Reznikov LL, Dinarello CA, Harken AH, McCarter MD. Melanoma inhibits macrophage activation by suppressing toll-like receptor 4 signaling. J Am Coll Surg. 2005 Sep; 201(3):418-25.
    View in: PubMed
    Score: 0.054
  9. McKenzie RC, Oran A, Dinarello CA, Sauder DN. Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo. Anticancer Res. 1996 Jan-Feb; 16(1):437-41.
    View in: PubMed
    Score: 0.028
  10. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003 Mar 04; 100(5):2645-50.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)